Albany Molecular Research has begun the process of manufacturing a 200g demonstration batch of psilocybin for Tryp Therapeutics. This is the first step in the company’s plan to manufacture batches of Tryp’s proprietary formulation of cGMP psilocybin, TRP-8802. La Jolla, California–(Newsfile Corp. – February 16, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp” or the “Company”) a pharmaceutical…


Previous articleComparing 18-MC vs. Ibogaine for the Treatment of Substance Use Disorder
Next articlePT231 – Dr. Hassan Tetteh – Human Care Over Health Care